Surrozen, Inc. (SRZN)

NCM – Real vaqt narxi. Valyuta: USD

30.66

+1.38 (4.71%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

06.05.2026

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the first quarter ended March 31, 2026 and provided a business update.

28.04.2026

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of 2,020 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.

14.04.2026

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

23.03.2026

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update.

25.02.2026

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

23.02.2026

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

28.04.2026

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23.03.2026

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

23.02.2026

Surrozen, Inc. (SRZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Surrozen, Inc. (SRZN)

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Surrozen, Inc. (SRZN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Surrozen, Inc. (SRZN)

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)